Cargando…
Pilot study with pegylated liposomal doxorubicin for advanced or unresectable hepatocellular carcinoma
We performed a pilot-study on pegylated liposomal doxorubicin (PLD) for advanced hepatocellular carcinoma. Seventeen patients received 40 mg/m(2) PLD intravenously every 4 weeks. A clinical benefit response was achieved in 50% (complete remission 7%, minor remission 7%, stable disease 36%). Toxiciti...
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group
2001
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2364023/ https://www.ncbi.nlm.nih.gov/pubmed/11747325 http://dx.doi.org/10.1054/bjoc.2001.2149 |